A new blood test for early detection of Alzheimer's Disease
A new diagnostic test for AD based on a neurotoxic Abeta Dimer
This study is working on a new blood test that can help find Alzheimer's Disease early by checking for a specific marker in your blood, making it easier to catch the disease sooner and manage it better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10885287 on NIH RePORTER |
What this research studies
This research focuses on developing a novel blood test that can detect Alzheimer's Disease (AD) at an early stage by measuring a specific neurotoxic peptide dimer associated with the disease. The approach involves analyzing blood samples to identify levels of this newly discovered biomarker, which may reflect amyloid accumulation in the brain more accurately than current methods. By improving early detection, the research aims to facilitate timely interventions and monitoring of AD progression. The study will utilize advanced biochemical techniques to validate the effectiveness of this blood test compared to existing diagnostic methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's Disease, particularly those with a family history or early cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's Disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a reliable blood test for early diagnosis of Alzheimer's Disease, enabling earlier treatment and better management of the condition.
How similar studies have performed: Previous research has shown promise in developing blood-based biomarkers for Alzheimer's Disease, but this specific approach using the crosslinked Aβ dimer is novel.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Schey, Kevin L — Vanderbilt University
- Study coordinator: Schey, Kevin L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.